The murine CD94/NKG2 ligand, Qa-1β, is a high-affinity, functional ligand for the CD8αα homodimer

The immune co-receptor CD8 molecule (CD8) has two subunits, CD8α and CD8β, which can assemble into homo or heterodimers. Nonclassical (class-Ib) major histocompatibility complex (MHC) molecules (MHC-Ibs) have recently been identified as ligands for the CD8αα homodimer. This was demonstrated by the observation that histocompatibility 2, Q region locus 10 (H2-Q10) is a high-affinity ligand for CD8αα which also binds the MHC-Ib molecule H2-TL. This suggests that MHC-Ib proteins may be an extended source of CD8αα ligands. Expression of H2-T3/TL and H2-Q10 is restricted to the small intestine and liver, respectively, yet CD8αα-containing lymphocytes are present more broadly. Therefore, here we sought to determine whether murine CD8αα binds only to tissue-specific MHC-Ib molecules or also to ubiquitously expressed MHC-Ib molecules. Using recombinant proteins and surface plasmon resonance–based binding assays, we show that the MHC-Ib family furnishes multiple binding partners for murine CD8αα which also binds the MHC-Ib molecule H2-TL. This suggests that MHC-Ib proteins may be an extended source of CD8αα ligands. Expression of H2-T3/TL and H2-Q10 is restricted to the small intestine and liver, respectively, yet CD8αα-containing lymphocytes are present more broadly. Therefore, here we sought to determine whether murine CD8αα binds only to tissue-specific MHC-Ib molecules or also to ubiquitously expressed MHC-Ib molecules. Using recombinant proteins and surface plasmon resonance–based binding assays, we show that the MHC-Ib family furnishes multiple binding partners for murine CD8αα, including H2-T22 and the CD94/NKG2-A/B-activating NK receptor (NKG2) ligand Qa-1β. We also demonstrate a hierarchy among MHC-Ib proteins with respect to CD8αα binding, in which Qa-1β > H2-Q10 > TL. Finally, we provide evidence that Qa-1β is a functional ligand for CD8αα, distinguishing it from its human homologue MHC class I antigen E (HLA-E). These findings provide additional clues as to how CD8αα-expressing cells are controlled in different tissues. They also highlight an unexpected immunological divergence of Qa-1β/HLA-E function, indicating the need for more robust studies of murine MHC-Ib proteins as models for human disease.

There are two distinct subunits of CD8, termed CD8α and CD8β. These can assemble into CD8αα homodimers or CD8αβ heterodimers (1, 2). The CD8αβ heterodimer interacts with class I MHC molecules, providing co-stimulation. In contrast, the precise function of the CD8αα homodimer is unknown, but it is thought to act as a co-repressor (3). Although T cells expressing CD8αβ are primarily TCRαβ+ and account for the vast majority of peripheral CD8 T cells (2, 4), CD8αα homodimers are the principal recognition element for a large proportion of intestinal epithelial lymphocytes, peripheral TCRγδ T cells and activated TCRγδ CD8 T cells (5–10). The only known ligands for CD8αα are H2-T3/TL (11) and H2-Q10 (12) and these belong to the nonclassical class I or MHC-Ib family.

MHC-Ib are less polymorphic than class Ia and can demonstrate cellular and tissue specificity (13, 14). This allows them to serve more diverse and specialized functions than their class Ia counterparts, whose primary role is the presentation of intracellular peptides to CD8 T cells. For example, H2-T3/TL is restricted to epithelial cells of the intestine (15, 16), H2-Q10 is a soluble MHC (17, 18) that is overexpressed in the liver (19), and H2-T13 is only expressed in the blastocyst and placenta (20). In contrast, H2-M3 is widely expressed (13) but is restricted to the presentation of N-formylated peptides, making it a recognition element for CD8 T cells directed at intracellular bacteria (21). Similarly, Qa-1β is ubiquitously expressed (13) and acts to present the leader sequence from class Ia MHC to subsets of natural killer (NK) and T cells expressing CD94/NKG2 heterodimers (22). In this regard, Qa-1β appears to be the sole homologue of a human MHC-Ib, HLA-E, with which it shares its function (22, 23). As such, studies using Qa-1β have been heavily utilized as preclinical models for HLA-E responses to a variety of infections and cancers (24, 25).

The observation that H2-T3/TL and H2-Q10 demonstrate tissue-restricted expression whereas CD8αα-expressing cells are distributed throughout nonlymphoid organs suggested that other MHC-Ib could act as ligands for CD8αα. Our results support this hypothesis and demonstrate that the interaction between MHC-Ib and CD8αα occurs within a hierarchical framework. Surface plasmon resonance demonstrated that Qa-1β had the highest affinity for CD8αα and was also capable of activating CD8αα expressing T cells. These interactions indicate that CD8αα ligands are more widespread than previously anticipated. Importantly, they also demonstrate a functional resonance; MFI, median fluorescent intensity; CMV, cytomegalovirus; MCMV, murine CMV; HCMV, human CMV; MSCV, murine stem cell virus; RU, response units.
Qa-1b as a ligand for CD8αα

Results

MHC-Ib are an extended family of ligands for CD8αα

To determine the potential for MHC-Ib to bind CD8, we first generated RMA-s cells expressing CD8αα (Fig. 1a), which were then stained with our panel of MHC-Ib tetramers (Fig. 1b). In line with previous data that demonstrated a weak affinity for CD8αα (11), we observed no binding of class Ia H-2Kb tetramers to RMA-s–CD8αα cells. Our results demonstrated a specificity among MHC-Ib for CD8αα with binding observed for H2-T22, TL, H2-Q10, and Qa-1b, but not Qa-2 or H2-M3 (Fig. 1b). Furthermore, analysis of the histograms suggested that H2-Q10 and Qa-1b bound to RMA-s–CD8αα cells better than H2-T3/TL. Comparison of median fluorescent intensity (MFI) staining across multiple experiments demonstrated a significant increase in the MFI between H2-T3/TL and H2-Q10 or Qa-1b (**, \( p = 0.0079 \)) as well as between H2-Q10 and Qa-1b (*, \( p = 0.0476 \)) (Fig. 1c).

Qa-1b as a ligand for CD8αα demonstrates intermolecular divergence between Qa-1b and HLA-E and highlight the need for more robust studies of murine MHC-Ib as models for human disease.

Qa-1b binds CD8αα with a higher affinity than H2-T3/TL and H2-Q10

We have previously demonstrated that the interaction between H2-Q10 and CD8αα is of a higher affinity (∼300 nM) than that between H2-T3/TL and CD8αα (∼800 nM) (12). Given these observations, we sought to determine the affinity between Qa-1b and CD8αα as a means to determine a binding hierarchy among H2-T3/TL, H2-Q10, and Qa-1b. When using Qa-1b as the ligand (Fig. 2a), the \( K_D \) calculated was ∼300 nM (averaged over several independent experiments, Fig. 2c), whereas using Qa-1b in the analyte phase (Fig. 2b), the \( K_D \) calculated was ∼200 nM (averaged over several independent experiments).
experiments, Fig. 2c). Therefore, the SPR in the two different orientations yielded broadly consistent results and reinforced our tetramer data. Collectively, the data from Figs. 1 and 2 demonstrate that MHC-Ib represents an extended family of ligands for CD8αα and that a hierarchy exists among these molecules with Qa-1b currently at the apex.

**MHC-Ib binds CD8αα on γδT cells with Qa-1b inducing IFN-γ production**

Having identified Qa-1b as a high-affinity ligand for CD8αα, we next sought to confirm this interaction directly *ex vivo*. To do this, we isolated lymphocytes from the small intestine of C57BL/6 mice in which a significant proportion of cells are TCRγδ+/CD8αα+ (Fig. 3a). Because lymphocytes from the gut also express CD94/NKG2 heterodimers and this can also bind Qa-1b (23), we separated intestinal lymphocytes into TCRγδ+/CD8αα+/CD94− (Fig. 3a). In line with our previous data, we observed that TCRγδ−/CD8αα+ cells bound TL, H2-Q10, and Qa-1b in a similar manner to that observed using SPR and our cell line. Sorting of TCRγδ+/CD8αα+ cells and culturing them in the presence of crosslinked Qa-1b resulted in the production of IFN-γ (Fig. 3b). This effect was not observed when TCRγδ−/CD8αα− cells were crosslinked (Fig. 3b), indicating specificity for CD8αα. These data highlight the capacity of Qa-1b to act as a functional ligand for TCRγδ+/CD8αα+ lymphocytes.

**HLA-E and Qa-1b differ in their ability to bind to CD8αα**

Finally, we sought to determine whether the interaction between Qa-1b and CD8αα was shared with their human counterparts. To do this, we generated Jurkat cells expressing homodimers of human CD8αα and stained them with tetramers of HLA-E, Qa-1b, and HLA-G (Fig. 4). In line with a previous study (26), we observed minimal binding of HLA-E and Qa-1b to human CD8αα. In contrast, we did observe binding of the known human CD8αα ligand HLA-G (Fig. 4a). Examination of the reverse interaction indicated that HLA-E and HLA-G had minimal binding to mouse CD8αα (Fig. 4b). These data demonstrate that the interaction between Qa-1b and CD8αα is highly specific and suggest a significant divergence between Qa-1b and HLA-E with respect to CD8αα binding.

**Discussion**

Our data provide new evidence that the mouse MHC-Ib provides multiple ligands for CD8αα, expanding on previous observations that identified the prototypical ligand, H2-TL (10, 27, 28) and H2-Q10 (24). The expression pattern of H2-TL is restricted to epithelial cells of the small intestine (15, 16), where it plays a central role in the activation of CD8αα+ cells (29), whereas H2-Q10 is restricted to the liver (19), where it regulates the development of CD8αα+ γδT cells. However, subsets of CD8αα+ cells exist in the lung and kidney (5–10), but none of these organs expresses H2-TL. Our observation that H2-T22 and Qa-1b are ligands for CD8αα now provides a rationale for the presence of CD8αα expressing cells outside of the small intestine and liver.

The signals controlling the development and activation of CD8αα expressing cells are not completely understood. These cells can be found in mice lacking all class I (30) as well as those lacking just class Ia MHC or H2-TL (29–32). This suggests that the role of MHC-Ib, and in particular Qa-1b, is more likely to be associated with controlling the responses of CD8αα expressing cells. Interestingly, the immune systems of Qa-1b−/− deficient mice develop normally but they do exhibit defects in secondary immune responses (33). The answer to this may lie within the capacity of activated CD8 T cells to up-regulate the CD8αα homodimer (10). Indeed, the expression of CD8αα promotes the survival and differentiation of memory T cell precursors (10). Although an up-regulation of H2-TL is observed on activated antigen-presenting cells (10), our new data suggest that the capacity of H2-TL to bind CD8αα on activated CD8 T cells would be outcompeted by Qa-1b. Qa-1b can also be up-regulated on antigen-presenting cells by the actions of TLR ligands and the presence of IFN-γ (34, 35), making it a likely target for activated T cells expressing CD8αα. Intriguingly, activated dendritic cells can stimulate the activation of Qa-1b restricted TCRγδ cells expressing CD8αα (36). These cells can then target and eliminate self-reactive CD4 T cell clones and attenuate the severity of experimental autoimmune encephalomyelitis (35). Although our experiments did not completely account for the co-expression of additional receptors that might also engage Qa-1b on CD8αα+ TCRγδ cells, our data convincingly showed that Qa-1b is a *bona fide* ligand for CD8αα itself. Hence, it will be interesting to determine whether CD8αα can act as a co-stimulator or co-repressor of the activation of Qa-1b restricted CD8αα+ TCRγδ cells. Given that CD8αα does not act as a co-receptor for CD8-dependent TCRs (37, 38) and that H2-TL is thought to act as a co-repressor (3), it is likely that the presence of CD8αα on these Qa-1b-restricted T cells is limiting their functionality. In addition, it will be important to determine whether binding can occur between Qa-1b and the CD8αβ heterodimer. It would be expected that if Qa-1b can interact with CD8αβ, it would be at a significantly lower affinity than to CD8αα, to prevent CD8αβ+ T cells from becoming activated by the presence of Qa-1b.
Qa-1b as a ligand for CD8αα

Figure 3. MHC-Ib binds CD8αα on γδT cells with Qa-1b inducing IFN-γ production. a, the pattern of MHC-Ib binding to CD8αα γδT cells is similar to that observed for RMA-s-CD8αα cells. FACS analysis of small intestine identifies a population of CD8αα+/CD94− γδT cells that bind MHC-Ib tetramers. Contour plots show the staining for CD3γδ/TCRγδ cells (left panel), their expression of CD8αα and the delineation of CD8αα+/CD94− and CD8αα+/CD94+ subsets. The arrows show the pattern of electronic gating. Staining of TCRγδ+ /CD8αα+ /CD94− cells with TL, H2-Q10, and Qa-1b demonstrates increased binding of Qa-1b when compared with H2-Q10 and TL. The open histogram is un stained, the filled histogram is TL, the dark-shaded histogram is H2-10 and the light-shaded histogram is Qa-1b. Numbers in the histogram are the median fluorescent intensity. Results are representative of at least four independent experiments. All histograms have been offset to stack vertically above one another and scaled to maximum count for clarity. Tetramer staining shows that HLA-E (open bars) or Qa-1b (gray bars) at 6 and 18 h post stimulation, the supernatants were harvested and cytokine production assessed using a CBA. The data are pooled from two independent experiments. 

Figure 4. Qa-1b and HLA-E differ in their ability to bind CD8αα. a, Jurkat cells were engineered to express human CD8αα (hCD8αα). Antibody staining shows a population of Jurkat-CD8αα cells with high expression of the CD8αα homodimer (left panel). The filled histogram is the unstained control whereas the open histogram is CD8 staining on Jurkat cells. The shaded histogram is CD8 staining on Jurkat-CD8αα cells. Results are representative of at least two independent experiments. All histograms have been offset to stack vertically above one another and scaled to maximum count for clarity. Tetramer staining shows that HLA-E and Qa-1b (second and third panels) have minimal binding to human CD8αα whereas HLA-G (right panel) interacts with human CD8αα. The filled histograms are the unstained controls whereas the open histograms are tetramer staining on Jurkat cells. The shaded histograms are tetramer staining on Jurkat-CD8αα cells. Results are representative of at least two independent experiments. All histograms have been offset to stack vertically above one another and scaled to maximum count for clarity. Tetramer staining shows that HLA-E (middle panel) and HLA-G (right panel) do not bind mouse CD8αα. The filled histograms are the unstained controls whereas the open histograms are tetramer staining on RMA-s cells. The shaded histograms are tetramer staining on RMA-s-CD8αα cells. Results are representative of at least three independent experiments. All histograms have been offset to stack vertically above one another and scaled to maximum count for clarity.

Complicating the study of Qa-1b and CD8αα in vivo are the observations that Qa-1b also binds CD94/NKG2 complexes (22, 39) and the TCR (37). Importantly, HLA-E also binds CD94/NKG2 (23) and the TCR (40) but not CD8αα (Fig. 4). What our data suggest is that Qa-1b will preferentially bind CD8αα over CD94/NKG2A as the affinity between Qa-1b and CD8αα is two orders of magnitude higher than that between Qa-1b and CD94/NKG2A (~17 μM for CD94/NKG2A) (41). The affinity of Qa-1b-restricted TCRs is yet to be determined but recognition of HLA-E by CMV-specific TCRs ranges from 3 to 37 μM (38, 40). Should these affinities be reflective of those between murine TCRs and Qa-1b, this suggests that a TCR-independent interaction with CD8αα will predominate. However, further exploration of the responses controlled by Qa-1b...
will require a better understanding of the biochemical partners involved in binding. The observation that CD8αα binds to the α3 region of the MHC (28), whereas CD94/NKG2 and the TCR bind to the α1–2 regions (41, 42) provides a basis for future studies in this area.

The generation of mice in which the Qa-1b/HLA-E interaction is abolished will be an important approach given the observation that Qa-1b is a high-affinity ligand for CD8αα, whereas HLA-E is not. This is especially relevant given the interest in γδT cells during cytomegalovirus (CMV) infection. Recent evidence has demonstrated that γδT cells confer protection against murine cytomegalovirus infection (MCMV) (43) and the expansion of γδT cell subsets is also associated with the resolution of human cytomegalovirus infection (HCMV) (44). On the flip side, HCMV infection is known to cause a specific CD8αα dependence in the generation of preclinical mouse models that are a more faithful representation of the human condition. The generation of mice in which the Qa-1b CD8αα interaction is abolished will be an important approach given the observation that Qa-1b is a high-affinity ligand for CD8αα, whereas HLA-E is not. This is especially relevant given the interest in γδT cells during cytomegalovirus (CMV) infection. Recent evidence has demonstrated that γδT cells confer protection against murine cytomegalovirus infection (MCMV) (43) and the expansion of γδT cell subsets is also associated with the resolution of human cytomegalovirus infection (HCMV) (44). On the flip side, HCMV infection is known to cause a specific CD8αα dependence in the generation of preclinical mouse models that are a more faithful representation of the human condition. 

Given that CD8αα recognition occurs within a hierarchy, further investigation into other members of the mouse MHC-Ib is required. We currently understand the basic biochemistry and immunology of only 6 of the 30 MHC-Ib, hence the capacity for future research into the function of this family is warranted. Indeed, it remains possible that many other members of the MHC-Ib family bind CD8αα, and even that another MHC-Ib may eclipse Qa-1b as the apex partner.

**Experimental procedures**

**Mice**

C57BL/6 mice were from Alfred Medical Research and Education Precinct (AMREP) Animal services. All mice were used at between 6 and 8 weeks of age. All experiments were in accordance with the animal ethics guidelines of the National Health and Medical Research Council of Australia and were approved by the AMREP Animal Ethics Committee.

**Cell culture**

RMA-s and Jurkat cells were sourced from the Peter MacCallum Cancer Centre Tumor cell bank. Cells were cultured in RPMI supplemented with 10% FCS, L-glutamine, penicillin and streptomycin. 293T and Phoenix E cells were cultured in DMEM supplemented with 10% FCS, L-glutamine, penicillin and streptomycin.

**Cloning and expression of recombinant CD8**

A codon-optimized gene encoding the full-length mouse CD8α (NM_001081110.2) was purchased from GenScript (Piscataway, NJ) and ligated into MSCV vectors. Orientation and correct sequence was confirmed by DNA sequencing using T7 forward and reverse primers.

**Retroviral transduction**

Retroviral transduction was performed on RMA-s and Jurkat cells; retrovirus-containing supernatant was produced by transfecting packaging cells with murine stem cell virus–internal ribosome entry site–GFP (MSCV-I–GFP) or MSCV-I–mCherry using standard calcium phosphate transfection methods. Viral supernatant was used to transduce RMA-s and Jurkat cells on retronectin (TaKaRa Bio, Shiga, Japan) precoated plates (BD Biosciences). After 5–7 days, GFP only (CD8αα) events were subjected to two rounds of cell sorting (FACSAria, BD Biosciences) to produce stable cell lines. Expression of CD8αα was confirmed by flow cytometry.

**Generation of recombinant CD8αα**

The sequence of soluble mouse CD8αα, allele CD8A*02, was designed based on a previously published sequence to fold soluble mouse CD8αα/CD8β following *Escherichia coli* expression (50), GenBank accession number GQ247790.1, except for the following modifications whereby residue numbering is based on Kern *et al.* (50). (i) Cys-36 was mutated to Ser as based on crystal structures of CD8αα, Cys-36 is not involved in disulfide bonds (50, 51), and we suspected that mutating this residue might improve folding efficiency; (ii) the gene was shortened to cover residues Gly-5 to Lys-128, as in previously determined crystal structures that included mouse CD8αα or CD8β there were no data beyond this region; (iii) the gene was codon-optimized for *E. coli* expression by GenScript (Piscataway, NJ). The gene was purchased from GenScript (Piscataway, NJ) and subcloned into a pET30 expression vector, expressed in BL21 *E. coli* competent cells and purified from inclusion bodies. The inclusion bodies were solubilized in 6M guanidine-HCl and 120 mg/liter of total protein (split over three injections) was rapidly diluted in a buffer containing 0.4 M arginine hydrochloride, 100 mM Tris-HCl (pH 8), 2 mM EDTA, 3 mM reduced GSH, and 0.3 mM oxidized GSH and allowed to sit for 2–3 days at 4 °C. The refold was then dialyzed against 25 mM HEPES (pH 7.4) overnight, followed by filtration through a 0.45 μM filter. The CD8αα was purified by cation exchange using an SP-Sepharose column (Amersham Biosciences) and eluted using 25 mM HEPES containing a gradient of NaCl. The major peak was pooled, concentrated, and further purified by size exclusion chromatography using Superdex 75 column with a buffer containing 25 mM HEPES (pH 7.4) with 150 mM NaCl.

**Generation of tetramers**

cDNA encoding residues 20–274 of Qa-2, H2-Q10, H2-TL, and Qa-1b were generated by GenScript and cloned into a pUC57 vector. H2-M3 and H-2Kb were generated following reverse transcription of cDNA encoding residues 20–274. The cDNA encoding residues 20–274 of H2-T22 were provided by K. Christopher Garcia (Stanford University, CA). All MHC sequences were subcloned into a pET-30–based vector that allowed for an in-frame fusion of a substrate peptide for the...
enzyme BirA. The heavy chains of H-2Kb, Qa-2, H2-Q10, TL, H2-T22, Qa-1b, H2-M3, and mouse β2-microglobulin were expressed separately in E. coli, purified from inclusion bodies and refolded in the absence of peptide (H2-TL and H2-T22) or in the presence of OVA (SINFEKL) for H-2Kb, coflin (KLT-GIKHEL) for Qa-2, ribophorin (VGTINVDL) for H2-Q10, Qdm (AMAPRTTL) for Qa-1b, and LemA (FMIGWII) for H2-M3. Monomers were purified by anion exchange and size exclusion chromatography, prior to biotinylation with BirA. 100% biotinylation of monomers was confirmed using native gel shift analysis by combining monomer with unlabeled enzyme BirA. The heavy chains of H-2Kb, Qa-1b, and HLA-E had been crosslinked overnight at 4 °C. Activation and analysis of sorted γδ T cells—Sorted cells were cultured in RPMI supplemented with 10% FCS, L-glutamine, penicillin, and streptomycin. 10^6 CD8αα+ or CD8αα− subsets in 100 μl were added to U-bottom 96-well plates in which 5 μg/ml Qa-1b or HLA-E had been crosslinked overnight at 4 °C. Supernatants were harvested at 6 and 18 h post stimulation and frozen at −20 °C. The CBA Flex System Kit (BD Biosciences) was then used to measure IFN-γ production according to the manufacturer’s protocols.

Flow cytometric analysis of RMA-s and Jurkat—Cells were cultured in tissue culture flasks for 2 days prior to removal with Tryple (Invitrogen). Cells were washed twice in PBS and nonspecific binding blocked with 2.4G2. Cells were then stained with mAb to CD8α (mouse 53–6.72, human SK1; BioLegend, San Diego, CA), and tetramers prior to fixation in 2% paraformaldehyde. Cells were then washed twice in PBS, resuspended in FACS buffer and acquired on an LSR-II or X-20 Fortessa flow cytometer (BD Biosciences). Doublets were excluded using a FSC-A versus FSC-H profile to exclude debris. At least 10,000 gated events were collected for analysis.

Surface plasmon resonance
Surface plasmon resonance (SPR) was performed essentially as described (52) in two different orientations, one where Qa-1b was on the chip (ligand) and the other where Qa-1b was in solution (analyte). For Qa-1b in the ligand phase, biotinylated MHC was captured on the surface of a ProteOn NLC neutravidin chip (Bio-Rad, ~150 RU of each). An empty flow cell with neutravidin alone served as a control. Serially diluted CD8αα, produced as described above, was injected simultaneously over the control and test surfaces. To verify results, SPR was also performed in the reverse orientation. In these experiments, an antibody to CD8αα (53–6.72) was amine coupled to two flow cells of a ProteOn GLC chip (~500 RU) and recombinant CD8αα was injected over the chip at 30 μl/min, and ~500 RU was captured by the antibody. The running and sample buffer was 10 mM HEPES (pH 7.4), 150 mM NaCl, and 0.05% Tween-20. The other flow cell containing antibody alone served as a control cell. Qa-1b was then injected over both flow cells. After subtraction of data from the control flow cells, Kd was calculated by kinetic analysis using the ProteOn Manager software (Bio-Rad). At least two independent SPR experiments were performed in both orientations.

Statistical analysis
The nonparametric, two-tailed Mann-Whitney U test was used to determine the statistical significance of data sets; p values of less than 0.05 were considered significant.

Author contributions—K. J. G., L. C. S., and D. M. A. conceptualization; K. J. G., A. N., C. M., S. B. G. E., L. C. S., and D. M. A. data curation; K. J. G., L. C. S., and D. M. A. formal analysis; K. J. G., L. C. S., and D. M. A. validation; K. J. G., A. N., C. M., S. B. G. E., L. C. S., and D. M. A. investigation; K. J. G. and D. M. A. visualization; K. J. G., A. N., C. M., S. B. G. E., L. C. S., and D. M. A. methodology; K. J. G. writing-original draft; K. J. G. and D. M. A. project administration; K. J. G., A. N., L. C. S., and D. M. A. writing-review and editing; L. C. S. and D. M. A. funding acquisition; D. M. A. resources; D. M. A. supervision.

Acknowledgments—We thank the members of the Alfred Medical Research and Education Precinct (AMREP) Flow Cytometry unit and the Monash Animal Research Platform.

References
1. DiSanto, J. P., Knowles, R. W., and Flomenberg, N. (1988) The human Lyt-3 molecule requires CD8 for cell surface expression. EMBO J. 7, 3465–3470 CrossRef Medline
2. Norment, A. M., and Littman, D. R. (1988) A second subunit of CD8 is expressed in human T cells. EMBO J. 7, 3433–3439 CrossRef Medline
3. Cherouet, H., and Lambeaux, F. (2008) Doubting the TCR coreceptor function of CD8αα. Immunity 28, 149–159 CrossRef Medline
4. Torres-Nagel, N., Kraus, E., Brown, M. H., Tiefenthaler, G., Mitnacht, R., Williams, A. F., and Hünig, T. (1992) Differential thymus dependence of rat CD8 isoform expression. Eur. J. Immunol. 22, 2841–2848 CrossRef Medline
5. Guy-Grand, D., Cerf-Bensussan, N., Malissen, B., Malassis-Seris, M., Briottet, C., and Vassalli, P. (1991) Two gut intraepithelial CD8+ lymphocyte populations with different T cell receptors: A role for the gut epithelium in T cell differentiation. J. Exp. Med. 173, 471–481 CrossRef Medline
19. Cosman, D., Kress, M., Khoury, G., and Jay, G. (1982) Tissue-specific expression of the murine soluble class I molecule (Q10). J. Immunol. 136, 254–258

20. Cosman, D., Kress, M., Khoury, G., and Jay, G. (1982) Tissue-specific expression of an unusual H-2 (class I)-related gene. Proc. Natl. Acad. Sci. U.S.A. 79, 4947–4951

21. Wang, C. R., Castaño, A. R., Peterson, P. A., Slaughter, C., Lindahl, K. F., and Deisenhofer, J. (1995) Nonclassical binding of formylated peptide in a complex class I b gene expressed in the mouse blastocyst and placenta. Proc. Natl. Acad. Sci. U.S.A. 92, 31–38

22. Compton, D., Sun, K., and Deisenhofer, J. (1995) Nonclassical binding of formylated peptide in a complex class I b gene expressed in the mouse blastocyst and placenta. Proc. Natl. Acad. Sci. U.S.A. 92, 31–38

23. Wang, C. R., Castaño, A. R., Peterson, P. A., Slaughter, C., Lindahl, K. F., and Deisenhofer, J. (1995) Nonclassical binding of formylated peptide in a complex class I b gene expressed in the mouse blastocyst and placenta. Proc. Natl. Acad. Sci. U.S.A. 92, 31–38

24. Goodall, K. J., Nguyen, A., Sullivan, L. C., and Andrews, D. M. (2018) The expanding role of murine class Ib MHC in the development and activation of natural killer cells. Mol. Immunol. 115, 31–38

25. Godfrey, D. I., Le Nours, J., Andrews, D. M., Uldrich, A. P., and Rossjohn, J. (2018) Unconventional T cell targets for cancer immunotherapy. Immunity 48, 453–473

26. Gao, G. F., Wilcoxon, B. E., Wyer, J. R., Boulter, J. M., O’Callaghan, C. A., Maenaka, K., Stuart, D. I., Jones, E. Y., Van Der Merwe, P. A., Bell, J. I., and Jakobsen, B. K. (2000) Classical and nonclassical class I major histocompatibility complex molecules exhibit subtle conformational differences that affect binding to CD8αα. J. Biol. Chem. 275, 15232–15238

27. Attigter, A., Devine, L., Wang-Zhu, Y., Martin, D., Wang, J. H., Reinherz, E. L., Kronenberg, M., Cheroutre, H., and Kay, A. (2003) Tissue-specific expression of HLA-E mediates differential and CD8αα-mediated survival and differentiation of CD8 T cell precursors. Science 304, 590–593

28. Oliveira-Villagómez, D., Mendez-Fernandez, Y. V., Parekh, V. V., Lalani, S., Vincent, T. L., Cheroutre, H., and Vaer, L. (2008) Thymus leukemia antigen controls intraepithelial lymphocyte function and inflammatory bowel disease. Proc. Natl. Acad. Sci. U.S.A. 105, 17931–17936

29. Correct, L., Bix, M., Liao, N. S., Zijlstra, M., Jaenisch, R., and Raulet, D. (1992) Most γδ T cells develop normally in β2-microglobulin-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 89, 653–657

30. Gapin, L., Cheroutre, H., and Kronenberg, M. (1999) Cutting edge: TCR alpha beta + CD8 αα + T cells are found in intestinal intraepithelial lymphocytes of mice that lack classical MHC class I molecules. J. Immunol. 163, 4100–4104

31. Park, S. H., Guy-Grand, D., Lemmonier, F. A., Wang, C. R., Bendelac, A., and Jabri, B. (1999) Selection and expansion of CD8αα(1) T cell receptor αβ(1) intestinal intraepithelial lymphocytes in the absence of both classical major histocompatibility complex class I and nonclassical CD1 molecules. Immunity 10, 380–387

32. Hu, D., Ikizawa, K., Lu, L., Sanchirico, M. E., Shinozaka, M. L., and Cantor, H. (2004) Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat. Immunol. 5, 516–523

33. Colmenero, P., Zhang, A. L., Qian, T., Li, J., Cantor, H., Soderstrom, K., and Engleman, E. G. (2007) Qa-1-dependent modulation of dendritic cell and NK cell cross-talk in vivo. J. Immunol. 179, 4608–4615

34. Smith, T. R. F., Tang, X., Maricic, I., Garcia, Z., Fanchiang, S., and Kumar, V. (2009) Dendritic cells use endocytic pathway for cross-priming Class Ib MHC-restricted CD8αα + TCRαβ + T cells with regulatory properties. J. Immunol. 182, 6959–6968

35. Tang, X., Maricic, I., and Kumar, V. (2007) Anti-TCR antibody treatment activates a novel population of nonintestinal CD8αα + TCRαβ + regulatory cells and prevents autoimmune encéphalomyelitis. J. Immunol. 178, 6043–6050

36. McNeil, A. M., Bendle, G., Holier, A., Matjeka, T., Dalton, E., Rettig, L., Zamorsky, R., Uckert, W., Xue, S. A., and Stauss, H. J. (2007) CD8αα homodimers fail to function as co-receptor for a CD8-dependent TCR. Eur. J. Immunol. 37, 1634–1641

37. Sullivan, L. C., Walpole, N. G., Farenc, C., Pietra, G., Sum, M. J. W., Clements, C. S., Lee, E. J., Beddoo, T., Falco, M., Mingari, M. C., Moretta, L., Gras, S., Rossjohn, J., and Brooks, A. G. (2017) A conserved energetic footprint underpins recognition of human leukocyte antigen-ε by distinct ε8 T cell receptors. J. Biol. Chem. 292, 21149–21158

38. Doorduijn, E. M., Sluijter, M., Querido, B. J., Seidel, U. J. E., Oliveira, C. C., van der Burg, S. H., and van Hall, T. (2018) T cells engaging the conserved TCRαβ and the nonclassical MHC class I molecule, TL. J. Immunol. 199, 885–890

39. Sullivan, L. C., Walpole, N. G., Farenc, C., Pietra, G., Sum, M. J. W., Clements, C. S., Lee, E. J., Beddoo, T., Falco, M., Mingari, M. C., Moretta, L., Gras, S., Rossjohn, J., and Brooks, A. G. (2017) A conserved energetic footprint underpins recognition of human leukocyte antigen-ε by distinct ε8 T cell receptors. J. Biol. Chem. 292, 21149–21158

40. Hoare, H. L., Sullivan, L. C., Pietra, G., Clements, C. S., Lee, E. J., Ely, L. K., Beddoo, T., Falco, M., Kjer-Nielsen, L., Reid, H. H., McCluskey, J., Moretta, L., Rossjohn, J., and Brooks, A. G. (2006) Structural basis for a...
major histocompatibility complex class I b-restricted T cell response. *Nat. Immunol.* 7, 256–264 CrossRef Medline
41. Zeng, L., Sullivan, L. C., Vivian, J. P., Walpole, N. G., Harpur, C. M., Rossjohn, J., Clements, C. S., and Brooks, A. G. (2012) A structural basis for antigen presentation by the MHC class I b molecule, Qa-1b. *J. Immunol.* 188, 302–310 CrossRef Medline
42. Kaiser, B. K., Pizarro, J. C., Kerns, J., and Strong, R. K. (2008) Structural basis for NKG2A/CD94 recognition of HLA-E. *Proc. Natl. Acad. Sci. U.S.A.* 105, 6696–6701 CrossRef Medline
43. Khairallah, C., Netzer, S., Villacreces, A., Juzan, M., Rousseau, B., Dulanto, S., Giese, A., Costet, P., Praloran, V., Moreau, J. F., Dubus, P., Vermijlen, D., Déchanet-Merville, J., and Capone, M. (2015) γδ T cells confer protection against murine cytomegalovirus (MCMV). *PLoS Pathog.* 11, e1004702 CrossRef Medline
44. Lafarge, X., Merville, P., Cazin, M. C., Bergé, F., Potaux, L., Moreau, J. F., and Déchanet-Merville, J. (2001) Cytomegalovirus infection in transplant recipients resolves when circulating γδ T lymphocytes expand, suggesting a protective antiviral role. *J. Infect. Dis.* 184, 533–541 CrossRef Medline
45. Lopez-Vergès, S., Milush, J. M., Schwartz, B. S., Pando, M. J., Jarjoura, J., York, V. A., Houchins, J. P., Miller, S., Kang, S. M., Norris, P. J., Nixon, D. F., and Lanier, L. L. (2011) Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. *Proc. Natl. Acad. Sci. U.S.A.* 108, 14725–14732 CrossRef Medline
46. Della Chiesa, M., Sivori, S., Carlomagno, S., Moretta, L., and Moretta, A. (2015) Activating KIRs and NKG2C in viral infections: Toward NK cell memory? *Front. Immunol.* 6, 573 CrossRef Medline
47. Kadivar, M., Petersson, J., Svensson, L., and Marsal, J. (2016) CD8αβ+ γδ T cells: A novel T cell subset with a potential role in inflammatory bowel disease. *J. Immunol.* 197, 4584–4592 CrossRef Medline
48. Kenna, T., Golden-Mason, L., Norris, S., Hegarty, J. E., O’Farrelly, C., and Doherty, D. G. (2004) Distinct subpopulations of γδ T cells are present in normal and tumor-bearing human liver. *Clin. Immunol.* 113, 56–63 CrossRef Medline
49. Sullivan, L. C., Westall, G. P., Widjaja, J. M., Mifsud, N. A., Nguyen, T. H., Meehan, A. C., Kotsimbos, T. C., and Brooks, A. G. (2015) The presence of HLA-E-restricted, CMV-specific CD8+ T cells in the blood of lung transplant recipients correlates with chronic allograft rejection. *PLoS One* 10, e0135972 CrossRef Medline
50. Kern, P., Hussey, R. E., Spoerl, R., Reinherz, E. L., and Chang, H. C. (1999) Expression, purification, and functional analysis of murine ectodomain fragments of CD8αα and CD8αβ dimers. *J. Biol. Chem.* 274, 27237–27243 CrossRef Medline
51. Kern, P. S., Teng, M. K., Smolyar, A., Liu, J. H., Liu, J., Hussey, R. E., Spoerl, R., Chang, H. C., Reinherz, E. L., and Wang, J. H. (1998) Structural basis of CD8 coreceptor function revealed by crystallographic analysis of a murine CD8αα ectodomain fragment in complex with H-2Kb. *Immunity* 9, 519–530 CrossRef Medline
52. Andrews, D. M., Sullivan, L. C., Baschuk, N., Chan, C. J., Berry, R., Cotterell, C. L., Lin, J., Halse, H., Watt, S. V., Poursine-Laurent, J., Wang, C. R., Scalzo, A. A., Yokoyama, W. M., Rossjohn, J., Brooks, A. G., and Smyth, M. J. (2012) Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells. *Nat. Immunol.* 13, 1171–1177 CrossRef Medline.